REalWorld insights on the INitiation and treatment Duration of ticagrEloR & other oral antiplatelets in patients with acute coronary syndrome in Belgium/Luxembourg (REWINDER)
Treatment of Acute Coronary Syndrome (ACS).
ACS patients treated with OAP
18 Years - 150 Years
Endpoint Classification: -
Intervention Model: -
Primary Purpose: -
Verified 01 Jan 2016 by AstraZeneca
No locations available
|ACS patients treated with OAP|
Patients with ACS who have been initiated and treated with ticagrelor and other oral antiplatelets
Drug: ACS patients treated with OAP
Patients with ACS who have been initiated and treated with ticagrelor and other oral antiplatelets.